PROF

Investigation Announcement: Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Profound Medical Corp. following a disclosure of overstated revenue by $472,000 in early 2024.

Stock Impact: After the announcement of the financial error on March 7, 2025, Profound's stock price dropped by 5.9%, closing at $6.86 per share.

Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against Profound Medical Corp. following the company's admission of a $472,000 revenue overstatement in its first quarter of 2024.

Impact on Stock Price: As a result of the disclosure, Profound's shares dropped by 5.9% on the day of the announcement, and the company stated that its quarterly reports for the first three quarters of 2024 are no longer reliable for investors.

Investigation Announcement: Wolf Haldenstein Adler Freeman & Herz LLP is investigating claims of potential securities fraud involving Profound Medical Corp. after the company disclosed an error that overstated revenue by $472,000 in Q1 2024.

Impact on Stock: Following the announcement, shares of Profound Medical fell by 5.9%, and the company stated that its quarterly reports for the first three quarters of 2024 are no longer reliable for investors.

Investigation of Profound Medical Corp: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Profound Medical Corp following the company's disclosure of a $472,000 revenue overstatement in its financial reports for 2024.

Impact on Stock Price: Following the announcement of the error, Profound's stock price dropped by 5.9%, closing at $6.86 per share on March 7, 2025.

Investigation into Profound Medical Corp: Pomerantz LLP is investigating potential securities fraud and unlawful business practices by Profound Medical Corp following the company's disclosure of a $472,000 revenue overstatement in its financial reports for 2024.

Impact on Stock Price: Following the announcement of the financial error, Profound's stock price dropped by 5.9%, closing at $6.86 per share on March 7, 2025.

Investigation Announcement: Glancy Prongay & Murray LLP has initiated an investigation into Profound Medical Corp. for potential violations of federal securities laws following the company's disclosure of a $472,000 revenue overstatement in its financial statements.

Stock Impact: Following the announcement of the error, Profound's stock price dropped by 5.9%, closing at $6.86 per share, resulting in financial losses for investors.

Investigation Announcement: The Law Offices of Frank R. Cruz are investigating Profound Medical Corp. for potential violations of federal securities laws following the company's disclosure of a $472,000 revenue overstatement in Q1 2024.

Stock Impact: After the announcement of the error, Profound's stock price dropped by 5.9%, closing at $6.86 per share, resulting in financial losses for investors.

Investigation Announcement: Pomerantz LLP is investigating potential securities fraud claims against Profound Medical Corp. following the company's disclosure of a $472,000 revenue overstatement in its financial reports for 2024.

Stock Impact: As a result of the announcement, Profound's stock price dropped by 5.9%, closing at $6.86 per share on March 7, 2025.

Financial Results Announcement: Profound Medical Corp. will release its fourth quarter and full year 2024 financial results on March 6, 2025, followed by a conference call at 4:30 p.m. ET to discuss the results and business developments.

Product Overview: The company is commercializing TULSA-PRO®, a non-invasive treatment for prostate diseases, and Sonalleve®, a platform for treating uterine fibroids and bone metastases, both of which have received various regulatory approvals.

Fourth Quarter Revenue Growth: Profound Medical Corp. anticipates fourth quarter 2024 revenue growth of 105% to 110% year-over-year, with total revenue expected between $4.1 million and $4.2 million, contributing to an estimated full year revenue of approximately $11.1 million to $11.2 million.

Reporting Changes and Upcoming Presentation: Starting January 1, 2025, Profound will report financial results in accordance with U.S. GAAP and file with the SEC, while also announcing its presentation at the JPM 2025 conference on January 16, 2025.

Q4 Revenue Performance: Profound Medical reported preliminary Q4 revenue between $4.1 million and $4.2 million, slightly below the consensus estimate of $4.23 million, but showing significant annual growth of 105% to 110% and sequential growth of 45% to 48%.

Future Financial Reporting Changes: The company anticipates FY24 total revenue of approximately $11.1 million to $11.2 million, and will begin reporting financial results in accordance with U.S. GAAP starting January 1, 2025.

Company Presentation: Profound Medical Corp. will present an update on its business at the 43rd Annual J.P. Morgan Healthcare Conference on January 16, 2025, which will be available for live streaming on their website.

Innovative Technologies: The company is commercializing TULSA-PRO® and Sonalleve®, both of which offer incision-free therapies for treating prostate diseases and uterine fibroids, respectively, with a focus on patient safety and quick recovery.

Public Offering Announcement: Profound Medical Corp. has successfully closed its underwritten public offering of common shares at a price of US$7.50 per share, raising approximately US$40.25 million in gross proceeds to support the commercialization and development of its medical technologies.

Use of Proceeds: The funds from the offering will be allocated for the continued commercialization of the TULSA-PRO® system in the U.S., global development of both the TULSA-PRO® and Sonalleve® systems, as well as general working capital and corporate purposes.

Public Offering Announcement: Profound Medical Corp. has priced an underwritten public offering of 4,666,700 common shares at US$7.50 each, aiming to raise approximately US$35 million for the commercialization and development of its medical technologies, TULSA-PRO® and Sonalleve®.

Prospectus Accessibility: The Base Shelf Prospectus and Final Prospectus Supplement will be available on SEDAR+ and EDGAR within two business days, providing detailed information about the offering and the company.

Offering Announcement: Profound Medical Corp. plans to offer common shares in an underwritten public offering, with a potential 30-day option for underwriters to purchase an additional 15% of the shares. The proceeds will support the commercialization and development of their medical devices, TULSA-PRO® and Sonalleve®.

Regulatory Filings: The company has filed a preliminary prospectus supplement and will file a subsequent prospectus supplement related to the offering, accessible on SEDAR+ and EDGAR, while emphasizing that no securities regulatory authority has approved or disapproved the contents of the announcement.

Partnership Announcement: Profound Medical Corp. has entered a co-sales and co-marketing agreement with Siemens Healthineers to commercialize a new MRI-guided prostate therapy solution that combines Profound's TULSA-PRO system with Siemens' Magnetom Free.Max scanner, enhancing treatment options for prostate disease.

Regulatory Support: The U.S. Centers for Medicare & Medicaid Services (CMS) has elevated the reimbursement level for the TULSA procedure to Urology APC Level 7, effective January 1, 2025, facilitating broader access to this innovative treatment across various healthcare settings.

New Software Module Announcement: Profound Medical Corp. is set to unveil its third TULSA-AI software module, UA Alignment Assistant, at the upcoming RSNA 2024 and SUO 2024 meetings, aimed at enhancing workflow consistency during the TULSA procedure for prostate treatment.

TULSA Procedure Overview: The TULSA procedure, utilizing real-time MRI guidance and ultrasound technology, offers a customizable, incision-free treatment option for various prostate conditions, ensuring minimal recovery time and preserving urinary and sexual function.

TULSA Procedure Reimbursement: The U.S. Centers for Medicare and Medicaid Services (CMS) has established a new Category 1 CPT® code for the Transurethral Ultrasound Ablation (TULSA) procedure, effective January 1, 2025, which will allow for reimbursement in various treatment settings including hospitals and surgical centers.

Financial Impact and Benefits: TULSA's reimbursement rates are significantly higher than previous treatments for prostate conditions, with payments set at $12,992 for hospital outpatient services and $10,728 for ambulatory surgical centers, reflecting an increase of approximately 41% and 49%, respectively, compared to earlier proposals.

Upcoming Financial Results Announcement: Profound Medical Corp. will announce its third quarter 2024 financial results on November 7, 2024, followed by a conference call to discuss the results and business developments.

Innovative Medical Technologies: The company is commercializing TULSA-PRO®, a non-invasive treatment for prostate diseases, and Sonalleve®, a platform for treating uterine fibroids and palliative pain, both of which have received various regulatory approvals.

New Appointment: Profound Medical Corp. has appointed Tom Tamberrino as Chief Commercial Officer, transitioning Abbey Goodman to lead strategic partnerships, as the company prepares for the permanent CPT Category 1 codes for TULSA in 2025.

Background and Expectations: Tamberrino brings extensive experience from NOVADAQ Technologies and is expected to enhance the adoption of TULSA technology, which offers a non-invasive treatment for prostate diseases, while also addressing reimbursement challenges.